NCT04840901View on ClinicalTrials.gov

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

242

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

February 11, 2022

Study Completion Date

February 11, 2022

Conditions

Healthy

Interventions

DRUG

Lebrikizumab

Administered SC.

Trial Locations (4)

32117

LabCorp CRU, Inc., Daytona Beach

53704

LabCorp CRU, Inc., Madison

65802

QPS, Springfield

75247

Covance Dallas, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY